Arch Biopartners Stock Price, News & Analysis

Arch Biopartners Inc. has filed a new provisional patent application to protect antibody drug candidates targeting inflammation mediated by dipeptidase-1 (DPEP-1) in the lungs, liver, and kidneys. This filing enhances its patent portfolio and introduces a novel class of therapeutics alongside existing peptide candidates. The company also concludes patient recruitment for its Phase II trial of LSALT peptide (Metablok), which aims to prevent organ inflammation in COVID-19 patients. The trial's results will inform the design of future Phase III studies.

Arch Biopartners Inc. (ACHFF) has completed enrollment for its Phase II trial of Metablok (LSALT Peptide), aimed at treating acute lung and kidney injuries caused by inflammation in severe COVID-19 cases. A total of 65 patients participated, with results expected in July 2021. The trial is designed to assess Metablok's efficacy in preventing organ inflammation that can lead to severe complications in COVID-19 patients. Positive outcomes may inform a Phase III program with a larger patient cohort.

Arch Biopartners has entered an exclusive global license agreement with Telara Pharma to develop cilastatin, a small-molecule drug aimed at preventing acute kidney injury (AKI). This collaboration unifies existing patents and supports a new Phase II trial targeting AKI, a condition affecting 10-15% of hospitalized patients, with a market valued over $20 billion. Cilastatin, previously used in combination with imipenem, inhibits dipeptidase-1 (DPEP-1), an adhesion receptor linked to inflammation. Arch's Metablok is also in trials addressing similar pathways.

Arch Biopartners Inc. (OTCQB: ACHFF) received approval from the Turkish Ministry of Health to double patient recruitment for its Phase II trial of LSALT peptide (Metablok), targeting acute lung and kidney injuries linked to severe COVID-19 cases. The trial now allows for 40 patients in Turkey, with the first 20 having completed treatment. The ongoing surge in COVID-19 cases in Turkey, exceeding 32,000 daily infections, emphasizes the trial's urgency. As of now, 46 patients have been recruited across North America and Turkey, aiming to demonstrate Metablok's efficacy in preventing organ inflammation.

Arch Biopartners Inc. (ACHFF) has received a No Objection Letter from Health Canada regarding protocol amendments for its Phase II trial of LSALT peptide (Metablok), which targets organ inflammation in severe COVID-19 cases. Changes include lowering the minimum patient age from 45 to 18 and simplifying the treatment regimen. These modifications aim to enhance enrollment and patient care in the study. The amended protocol will be submitted to the U.S. FDA and Turkish Ministry of Health. The trial is crucial for evaluating Metablok's effectiveness against acute lung and kidney injuries in COVID-19 patients.

Arch Biopartners Inc. announced the publication of a paper by Dr. Daniel Hassett, demonstrating that AB569 effectively kills multi-drug resistant Acinetobacter baumannii and Acinetobacter spp. pathogens in combat wounds. These bacteria pose significant infection risks to military personnel. Arch is exploring human trials for AB569 as a topical treatment for wound infections, diabetic wounds, and potentially as a solution for urinary tract and lung infections. The company emphasizes the urgent need for innovative antimicrobial solutions amid rising antibiotic resistance.

Arch Biopartners Inc. announced that the Peter Lougheed Center in Calgary has joined its Phase II trial for the LSALT peptide (Metablok), aimed at preventing acute lung and kidney injuries in COVID-19 patients. This center is the second in Calgary to participate, following the University of Calgary's Foothills Medical Centre. Patient enrollment is ongoing in the U.S., while Turkish sites await health ministry approval for expansion. The trial aims to evaluate LSALT peptide's efficacy and safety in reducing organ inflammation associated with severe COVID-19 outcomes.

Arch Biopartners Inc. has commenced its Phase II trial of LSALT peptide, aimed at preventing acute lung and kidney injuries in COVID-19 patients. The first patient was dosed at Broward Health Medical Center, with recruitment expanding soon to Louisiana and Turkey. This international, double-blind trial will assess LSALT's efficacy in mitigating severe organ inflammation connected to COVID-19 complications. Results will inform the design of a subsequent Phase III trial, which will involve a larger patient population.

Arch Biopartners Inc. (OTCQB: ACHFF) has received approval from Turkey's Ministry of Health to proceed with a Phase II trial for its LSALT peptide drug, targeting acute lung and kidney injuries related to COVID-19. Patient enrollment will commence in Istanbul and Ankara, amidst rising COVID-19 cases in Turkey. In the U.S., patient screening has begun at a hospital site in Florida, with plans to activate two more sites. The trial aims to assess the LSALT peptide's efficacy in preventing organ inflammation in COVID-19 patients, impacting future Phase III study designs.